A Platform, Not Just a Product
The mRNA vaccines developed at record speed during the COVID-19 pandemic demonstrated something more significant than a single successful vaccine: a genuinely flexible platform technology that can be rapidly adapted to target new pathogens by simply changing the genetic sequence encoded in the vaccine, rather than requiring the years-long redevelopment process traditional vaccine platforms often demand for each new target.
The Expanding Pipeline
Building on this proven platform, researchers are now developing mRNA vaccines against a wide range of targets beyond COVID, including seasonal influenza with the hope of more precisely matched, rapidly updatable annual vaccines, respiratory syncytial virus, and various other infectious diseases that have long evaded effective vaccination, alongside the personalized cancer vaccine applications generating separate excitement in oncology.
Realistic Expectations for the Platform
While the platform speed and flexibility are genuine advantages, each new mRNA vaccine still requires its own clinical trials to establish safety and efficacy for that specific target, meaning the platform accelerates certain development stages without eliminating the need for rigorous testing. As more mRNA vaccines complete this testing and reach approval across diverse diseases, the technology promise from the pandemic era is gradually being realized across a broadening range of applications. Facilities can source lab supplies and pharmacy supplies from our catalog.
